EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study



Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study



Journal of Infection and ChemoTherapy 11(6): 265-269



Bovine lactoferrin (bLF) has antibacterial activity against Helicobacter pylori in vitro and is effective to suppress bacterial colonization in mice. The aim of our study was to evaluate the efficacy of orally administered bLF on H. pylori colonization in humans by a randomized, double-blind, placebo-controlled study. Fifty-nine healthy subjects positive for H. pylori infection were recruited. Subjects were randomized into two groups.

(PDF emailed within 0-6 h: $19.90)

Accession: 011816296

Download citation: RISBibTeXText

PMID: 16369731

DOI: 10.1007/s10156-005-0407-x



Related references

Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 81(4): 387-393, 2007

Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study. Evidence-Based Complementary and Alternative Medicine 2013: 263805-263805, 2013

The recurrence of duodenal ulcer after treatment for Helicobacter pylori. A randomized, double-blind, placebo-controlled study. G.E.N 46(4): 302-306, 1992

Helicobacter pylori eradication for non-ulcer dyspepsia A prospective, double-blind, randomized, placebo controlled study. Gastroenterology 110(4 SUPPL ): A91, 1996

Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. Journal of Clinical Gastroenterology 48(5): 407-413, 2014

Helicobacter pylori eradication in non-ulcer dyspepsia A randomized, double-blind, placebo-controlled study with a 12-month follow-up. Gastroenterology 118(4 Suppl 2 Part 1): AGA A468, April, 2000

Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. Alimentary Pharmacology & Therapeutics 21(10): 1263-1272, 2005

Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Science 97(10): 1105-1110, 2006

Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 12(4): 309-316, 2007

Impact of bacillus clausii supplementation on anti helicobacter pylori therapy related side effects a randomized double blind placebo controlled study. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1498, 2003

Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. Phytomedicine 15(6-7): 391-399, 2008

Garlic in the treatment of Helicobacter pylori infection, a double blind randomized placebo controlled trial. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1289, April, 2000

Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. Bmc Gastroenterology 13: 56-56, 2013

Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. Digestive Diseases and Sciences 51(1): 89-98, 2006